Neupro Effective In Controlling Early Morning Motor Impairment And Generally Well-Tolerated For Long-Term Use In Patients With Parkinson’s Disease
Oct 10th 2007Drug InformationNeurology / Neuroscience
UCB, Inc. presented data from two clinical trials that showed NeuproŽ (Rotigotine Transdermal System), a once-daily non-ergolinic dopamine agonist patch, is effective in controlling early morning motor impairment, provides improvement in sleep quality, and is generally well-tolerated for long-term use in patients with Parkinson’s disease. Studies examining patients who have either early or advanced-stage Parkinson’s disease were also presented. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
